Medtronic had a superior solution to helping patients with aortic stenosis (narrowing the aortic valve, which limits blood flow from the heart to the rest of the body). Yet, as a new technology, physicians were skeptical. Medtronic needed to convince physicians their Evolut TAVR solution provided superior outcomes for patients.
Convince physicians that they can do more for patients with aortic stenosis and Medtronic’s one-of-a-kind Evolut TAVR solution can take patient outcomes further than ever before.
The campaign put people, not technology, first and educated physicians that beyond keeping patients alive, Evolut TAVR could dramatically increase the ability of patients to get back to doing the things they love.
Education was central to the campaign. The goal was to let physicians know that the Evolut TAVR procedure is superior to all others. It was a dramatic step forward in redefining how this disease state is treated.
Adoption of Evolut TAVR accelerated and has set the standard for the Aortic Stenosis treatment category.
